SUVEN
Suven Life Sciences Limited (SUVEN) Stock Analysis
Suven Life Sciences Limited conducts drug discovery research and contract research services for pharmaceutical clients. It operates discovery chemistry and clinical research capabilities with focus on CNS therapies. The company partners on innovative molecule development programs. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹285.40
-6.58% 1W | +44.20% 52W
Market Cap
8.1k CR
P/E Ratio
–
52W High
₹403.4
52W Low
₹124.1
Div. Yield
0%
Beta
0.9
50 DMA
₹340.4
200 DMA
₹243.4
Profit Margin
0%
Inst. Own.
1.2%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Expenses | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 |
| Operating Profit | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 |
| OPM % | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% | -3,711% |
| Other Income | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| Tax % | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| EPS in Rs | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 | -4.83 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 7 | 9 |
| Expenses | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 291 | 375 |
| Operating Profit | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -284 | -366 |
| OPM % | 31% | 20% | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,999% | -4,152% |
| Other Income | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 14 | 21 |
| Interest | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 | 6 |
| Profit before tax | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -276 | -352 |
| Tax % | 28% | 26% | 29% | 37% | 15,038% | -11% | -7% | 0% | 0% | -1% | 0% | 0% | |
| Net Profit | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -276 | -352 |
| EPS in Rs | 5.70 | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -10.48 | -14.44 |
| Dividend Payout % | 7% | 35% | 15% | 15% | -80% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -19.0% | -12.0% | -35.0% |
Shareholding Pattern
Promoters67.36%
FIIs1.17%
DIIs3.39%
Public28.07%
Promoters67.36%
FIIs1.07%
DIIs3.39%
Public28.18%
Promoters70.15%
FIIs0.91%
DIIs4.62%
Public24.32%
Promoters70.08%
FIIs0.56%
DIIs2.93%
Public26.42%
Promoters65.47%
FIIs0.48%
DIIs2.73%
Public31.32%
Promoters69.56%
FIIs0.51%
DIIs0.11%
Public29.80%
Promoters69.56%
FIIs0.46%
DIIs1.05%
Public28.91%
Promoters70.26%
FIIs0.25%
DIIs0.01%
Public29.47%
Promoters70.15%
FIIs0.91%
DIIs4.62%
Public24.32%
Promoters65.47%
FIIs0.48%
DIIs2.73%
Public31.32%
SUVEN
Holdings Analysis
Key strengths & risk signals
52
Overall
33
Fundamental
71
Technical
Risks (3)
LOW MARGIN! 0% profit margin - thin profits.
RECOVERY MODE! Current price (285.4) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 6.6% (1 week), 19.7% (1 month), 16.3% (3 months).
Strengths (3)
BULLISH TREND! 50-day average (340.4) is above 200-day average (243.4) - positive signal.
GOOD YEAR! Stock gained 44.2% in the last year.
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 687,512 vs down days: 510,154. Ratio: 1.35x
Fundamental & Technical Analysis
52Overall
33Fundamental
71Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -19.3% (DECLINING, 2/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
0/10
LOW MARGIN! 0% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 29.88% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (340.4) is above 200-day average (243.4) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (285.4) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
GOOD YEAR! Stock gained 44.2% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 687,512 vs down days: 510,154. Ratio: 1.35x
RSI
4/5
APPROACHING OVERSOLD! RSI at 30.7 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 57.8% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 6.6% (1 week), 19.7% (1 month), 16.3% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUVEN | ₹285.40 | – | – | -19.3% | – | +44.2% | 52 | BREAKDOWN | +147.8% | +179.8% | +89.5% | +140.0% |
| AARTIPHARM | ₹867.60 | 36.9 | 10.4% | -2.6% | -3.3% | +7.1% | 54 | APPROACHING RESISTANCE | +65.4% | +24.5% | +38.7% | -8.0% |
| PGHL | ₹5,232.50 | 24.3 | 24.9% | 8.2% | 19.3% | -15.7% | 76 | BREAKOUT | +45.3% | +1.7% | +7.4% | -1.8% |
| SEQUENT | ₹201.20 | 123.4 | 2.5% | 3.1% | -18.9% | +26.2% | 55 | CONSOLIDATION | -13.9% | +161.2% | +10.9% | +102.5% |
| BLISSGVS | ₹660.70 | 52.4 | 13.5% | 7.2% | 22.1% | +342.5% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| MOREPENLAB | ₹128.30 | 50.1 | 7.2% | 8.4% | 34.9% | +154.1% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| STAR | ₹1,084.80 | 16.3 | 12.3% | 8.7% | – | +37.8% | 68 | BREAKDOWN | +57.5% | +23.6% | +13.0% | -4.4% |
| SPARC | ₹191.80 | 3.9 | 83.0% | -45.3% | – | +40.8% | 60 | CONSOLIDATING DOWN | -59.9% | -101.2% | +315.6% | -97.8% |
Data from TradeAlone · Updated daily
SUVEN News
Suven Life Sciences Limited (suven) Completes Patient Enrollment in Global Phase-3 Study of Masupirdine for Agitation Associated with Alzheimer’s Dementia2026-09-03Suven Life Sciences Limited (suven) to Present Scientific Posters at Aaic-20262026-07-10Suven Life Sciences Limited (suven) to Showcase CNS Clinical Candidates at BIO International Convention 20262026-06-22Suven Life Sciences Limited Announces Positive Topline Results from Phase-2b Clinical Proof-of-concept Trial of Ropanicant for Major Depressive Disorder2026-06-17Suven Life Sciences Limited (suven) Announces Successful Completion of Phase-1 Study for Suvn-i61072026-06-16Suven Life Sciences Limited (suven) to Present Three Posters on Samelisant at Sleep-20262026-06-12Suven Life Sciences Limited (suven) Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Phase 3 Study of Masupirdine in Alzheimer’s Disease2026-06-04Suven Life Sciences Reaches 76% Enrollment in Global Phase 3 Masupirdine Trial2026-05-12
